GLG Partners’s Intellia Therapeutics NTLA Stock Holding History

GLG Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,697	Closed	-$100K	–	489
2016 Q2	$100K	Buy	+4,697	New	+$125K	﹤0.01%	395

Other funds holding NTLA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

GLG Partners's NTLA Position: Q3 2016 in Review

GLG Partners sold out of Intellia Therapeutics (NTLA) in Q3 2016, closing a stake of 4,697 shares — an estimated $100K sold.

GLG Partners first reported a position in NTLA in Q2 2016 and held it in 1 quarter. The position peaked at $100K in Q2 2016. 65 funds tracked by Wall St. Rank hold NTLA as of Q3 2016.

GLG Partners reported no remaining Intellia Therapeutics position as of Q3 2016 after selling out during the quarter.
GLG Partners sold 4,697 Intellia Therapeutics shares in Q3 2016, an estimated $100K.
GLG Partners first reported a position in Intellia Therapeutics in Q2 2016 and held it in 1 quarter.
GLG Partners's Intellia Therapeutics position peaked at $100K in Q2 2016.
65 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2016.

Based on GLG Partners's 13F filing for Q3 2016, filed 14 Nov 2016.